Related Experiment Video
Updated: May 4, 2026
Thermal Ablation for the Treatment of Abdominal Tumors
Published on: March 7, 2011
Osteoid osteoma treated by percutaneous thermal ablation: when do we fail? A systematic review and guidelines for
Ezio Lanza1, Yann Thouvenin, Pierre Viala
1Dipartimento di Scienze della Salute, Scuola di specializzazione in Radiodiagnostica, U.O. di Radiologia Diagnostica e Interventistica, Ospedale San Paolo, Università Degli Studi di Milano, Via Antonio di Rudinì, 8, 20142, Milan, Italy, eziolanza@gmail.com.
Purpose:
Osteoid osteoma (OO) is a painful benign bone tumor of the young that is widely treated by percutaneous thermal ablation (PTA) with success rates close to 100%. Nevertheless, some patients have recurrences. We reviewed the literature to understand whether these are true recurrences or incomplete treatments; to analyze safety and efficacy during long-term follow-up in a extremely large cohort of patients; to detail best-practice suggestions from the largest clinical trials as well as report their complications; and to recommend standards for future reporting.
Materials And Methods:
This study followed the Cochrane's guidelines for Systematic Reviews of Interventions. Inclusion criteria were as follows: (1) prospective or retrospective cohort study for PTA of OO under computed tomography (CT) guidance; (2) CT or magnetic resonance diagnosis; (3) radiofrequency ablation or interstitial laser ablation technique; (4) English language; (5) population <10 patients; (6) follow-up ≥12 months; and (7) original research. Risk of bias was assessed with a modified Newcastle-Ottawa Scale.
Results:
Two hundred fourteen articles were initially found. After applying the criteria mentioned previously, 27 PTA articles concerning 1,772 patients were chosen for inclusion. No exclusions were made due to risk of bias.
Conclusion:
The investigators proved the long-term efficacy and superiority of PTA for OO compared with other techniques. In 5% of patients, however, the technique failed, and the researchers did not offer detailed exhaustive explanations. Future clinical trials for OO ablation should consider reporting essential procedure details and follow-up findings to allow for a meta-analysis. We provide both recommended standards for future reporting and suggestions for the prevention of recurrence.
